# Trevi Therapeutics, Inc. (TRVI) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Trevi Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/TRVI/mda/fy2025/): filed 2026-03-17; accession 0001193125-26-110783 (https://www.sec.gov/Archives/edgar/data/1563880/000119312526110783/trvi-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/TRVI/mda/fy2024/): filed 2025-03-18; accession 0000950170-25-041194 (https://www.sec.gov/Archives/edgar/data/1563880/000095017025041194/trvi-20241231.htm)
- [FY 2023 MD&A](/company/TRVI/mda/fy2023/): filed 2024-03-20; accession 0000950170-24-034167 (https://www.sec.gov/Archives/edgar/data/1563880/000095017024034167/trvi-20231231.htm)
- [FY 2022 MD&A](/company/TRVI/mda/fy2022/): filed 2023-03-16; accession 0000950170-23-008472 (https://www.sec.gov/Archives/edgar/data/1563880/000095017023008472/trvi-20221231.htm)
- [FY 2021 MD&A](/company/TRVI/mda/fy2021/): filed 2022-03-17; accession 0001564590-22-010875 (https://www.sec.gov/Archives/edgar/data/1563880/000156459022010875/trvi-10k_20211231.htm)

Back to /company/TRVI/